Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK, safety and immunogenicity comparison of MB02 vs EU Avastin in healthy Japanese males
jRCT2080225005Phase 1Completed
- Sponsor
- mAbxience
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab MB02 in Neoplasm (2 arms), sponsored by mAbxience. Started Jan 2020; status: completed.
02
Drugs
bevacizumab MB02
03
Conditions
Neoplasm
Beyond the preview
Go deeper on jRCT2080225005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225005.